Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-75229414 |
| Synonyms | |
| Therapy Description |
JNJ-75229414 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets KLK2, which potentially induce toxicity against tumor cells expressing KLK2 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-75229414 | JNJ75229414|JNJ 75229414 | JNJ-75229414 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets KLK2, which potentially induce toxicity against tumor cells expressing KLK2 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05022849 | Phase I | JNJ-75229414 | A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants | Active, not recruiting | USA | 0 |